National Instruments
Share price: $60.00
Purchase-Price Allocation
Goodwill
$3.44B
Intangibles
$5.28B
Assets Acquired
$10.22B
Pro-Forma Combined Entity
Revenue
$17.51B
Net Income
+$1.98B
Diluted EPS
$3.45
2 years of history · ending 2025-09-30 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 0.60% | 0.50% | 0.70% | 0.80% | 0.60% | 1.80% |
| Foreign Rate Differential | 1.70% | 2.60% | 1.20% | 0.80% | 2.00% | 1.20% |
| Other Adjustments | 0.00% | 0.00% | 0.10% | 2.10% | 2.80% | 2.40% |
| R&D Tax Credits | 1.80% | 0.90% | 0.50% | 0.50% | 1.20% | 0.90% |
| FDII Deduction | — | 1.60% | 2.00% | 2.60% | 3.80% | 2.00% |
| Tax Law Change | 0.00% | — | — | — | — | — |
| Qualified Production Activities (Legacy DPAD) | 0.00% | — | — | — | — | — |
| Effective Tax Rate | 14.80% | 19.60% | 22.60% | 22.10% | 20.60% | 23.70% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $345.0M | $346.0M | $549.0M | $642.0M | $415.0M | $696.0M |
| Income Taxes Paid (Cash) | — | — | — | — | — | — |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Share price: $60.00
Purchase-Price Allocation
Goodwill
$3.44B
Intangibles
$5.28B
Assets Acquired
$10.22B
Pro-Forma Combined Entity
Revenue
$17.51B
Net Income
+$1.98B
Diluted EPS
$3.45
Purchase-Price Allocation
Goodwill
$424.0M
Purchase-Price Allocation
Goodwill
$32.0M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-09-30
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Employee Severance | Employee Severance | +$120M | $109M | $116M |
| Other Restructuring | Other | +$16M | $19M | $4M |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).